

DAFTAR PUSTAKA

- Abu-Rustum, N.R., Yashar, C.M., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S.M., Chino, J., Chon, H.S., Crispens, M.A. dan Damast, S., 2024. NCCN guidelines insights: cervical cancer, version 1.2024: featured updates to the NCCN guidelines. *Journal of National Comprehensive Cancer Network*, 21(12), pp.1224-1233.
- Agustiansyah, P., Sanif, R. dan Nurmaini, S., 2021. Epidemiology and risk factors for cervical cancer. *Bioscientia Medicina: Journal of Biomedicine and Translational Research*, 5(7), pp.624-631.
- Altun, I., Sonkaya, A., 2018. The most common side effects experienced by patients were receiving first cycle of chemotherapy. *Iranian journal of public health*, 47(8), p.1218.
- Amjad MT, Chidharla A, Kasi A. 2023. Cancer Chemotherapy. *StatPearls Publishing*; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK564367/>
- Anonim. 2024. Atezolizumab and bevacizumab. *Cancer Research UK*. Available from: <https://www.cancerresearchuk.org/about-cancer/treatment/drugs/atezolizumab-bevacizumab>.
- Anonim, 2024. Rencana Aksi Nasional Eliminasi Kanker Serviks 2023–2030. Kementrian Kesehatan RI.
- Anonim. 2025. Treatment for cancer: Chemotherapy. *Cancer Research UK*. Available from: <https://www.cancerresearchuk.org/about-cancer/treatment/chemotherapy>.

Argyriou, A.A., Bruna, J., Marmioli, P. and Cavaletti, G., 2012. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. *Critical reviews in oncology/hematology*, 82(1), pp.51-77.

Baroroh, I., 2023. Edukasi Kanker Serviks (Skrining, Diagnosa dan Pencegahan). *Jurnal ABDIMAS-HIP Pengabdian Kepada Masyarakat*, 4(1), pp.31-36.

Bray F, Ferlay J, Soerjomataram I, et al Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68:394–424. doi: 10.3322/caac.21492.

Bonlokke, S., Blaakaer, J., Steiniche, T. and Iachina, M., 2024. Social factors and age play a significant role in cervical cancer and advanced-stage disease among Danish women. *BMC cancer*, 24(1), p.259.

Bowen, R., Walther, A. 2018. Carboplatin, Paclitaxel and Bevacizumab. *National Health Service England*. Available from: <https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2018/11/Carboplatin-paclitaxel-bevacizumab2.pdf>.

Chan HK, Ismail S. 2014. Side effects of chemotherapy among cancer patients in a Malaysian General Hospital: experiences, perceptions and informational needs from clinical pharmacists. *Asian Pac J Cancer Prev*, 15(13):5305.

Cheng, M., Lee, H.H., Chang, W.H., Lee, N.R., Huang, H.Y., Chen, Y.J., Horng, H.C., Lee, W.L. dan Wang, P.H., 2019. Weekly dose-dense paclitaxel and triweekly low-dose cisplatin: a well-tolerated and effective chemotherapeutic regimen for first-line treatment of advanced ovarian, fallopian tube, and primary peritoneal

cancer. *International journal of environmental research and public health*, 16(23), p.4794.

Choi, I.J., Cha, M.S., Park, E.S., Han, M.S., Choi, Y., Je, G.H. and Kim, H.H., 2008.

The efficacy of concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. *Journal of Gynecologic Oncology*, 19(2), pp.129-134.

Choi PW, Liu TL, Wong CW, Liu SK, Lum YL, Ming WK., 2022 The Dysregulation of MicroRNAs in the Development of Cervical Pre-Cancer-An Update. *Int J Mol Sci*. Jun 27;23(13).

Chu, G., Liu, X., Yu, W., Chen, M. and Dong, L., 2021. Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study. *BMC cancer*, 21(1), p.133.

Danil, N., Arifuddin, S., Hartono, E., Rakhmah, N., Ajardiana, A., Rauf, S. dan Zainuddin, A.A., 2023. Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb. *Indonesian Journal of Obstetrics & Gynecology Science*, 6(1), pp.82-88.

Darmawan, E., Melani, R. dan Raharjo, B., 2019. Gambaran Hubungan Regimen Dosis Dan efek Samping Kemoterapi pada Pasien Kanker di RSUD Prof Dr. Margono Soekarjo Purwokerto Periode Bulan Januari-Februari Tahun 2019. *Majalah Farmaseutik*, 15(2), pp.113-122.

- Dasari, S. and Tchounwou, P.B., 2014. Cisplatin in cancer therapy: molecular mechanisms of action. *European journal of pharmacology*, 740, pp.364-378.
- Davidson, S., 2011. Treatment for advanced cervical cancer: Impact on quality of life. *Critical reviews in oncology/hematology*, 79(1), pp.24-30.
- DeVita, V. T., Lawrence, T. S., & Rosenberg, S. A. 2018. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (11th ed.). Wolters Kluwer.
- Dharmawan, F., 2025. Evaluasi Penggunaan Obat Kemoterapi Pada Pasien Kanker Serviks di RSUP Fatmawati Periode 1-30 September 2024. *Jurnal Farmasi Klinik Best Practice*, 4(1), pp.16-21.
- DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G. and Posey, L.M. eds., 2014. *Pharmacotherapy: a pathophysiologic approach*.
- Febriani, A. and Rahmawati, Y., 2019. Efek Samping Hematologi Akibat Kemoterapi dan Tatalaksananya. *Jurnal Respirasi*, 5(1), pp.22-28.
- Garcia, M.A., Kalecinski, J., Oriol, M., Bonne, A., Lofti, M., Espenel, S., Tinquaut, F., Fournel, P., Collard, O., Vassal, C. and Rivoirard, R., 2018. *Cancer patients treated with intravenous chemotherapy for the first time. What are their needs? What do they lack? A qualitative–quantitative mixed approach. Patient preference and adherence*, pp.1853-1861.
- Hannah, L. C. & Roman, B. R. (2024) Cervical Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK431093/> (Accessed: 3 October 2024).

- Hidayat, Y. M., 2013. Prinsip Dasar Kemoterapi. In Bandung Controversies and Consensus in Obstetrics & Gynecology (pp. 253-273). Jakarta: Sagung Seto.
- HOGI, P., 2018. Pedoman Nasional Pelayanan Kedokteran Kanker Ginekologi. Jakarta: PNPK HOGI.
- Irawati, Sardjan, M., 2022. Pola Peresepan Obat Kemoterapi Kanker Payudara di Rumah Sakit Lavalette Kota Malang. *Jurnal Kefarmasian dan Gizi*, 1(2), 80-85.
- Khabibah, U., Adyani, K. dan Rahmawati, A., 2022. Faktor Risiko Kanker Serviks: Literature Review. *Faletehan Health Journal*, 9(03), pp.270-277.
- Kim, M., Kwon, B.S., Chang, H.K., Lee, S., Chang, S.J., Choi, J.Y., Park, S.Y., Lee, M., Ryu, H.S. and Kim, Y.B., 2019. Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study. *Journal of Gynecologic Oncology*, 30(3).
- Kua, V.F., Ismail, F., Phua, V.C.E. and Aslan, N.M., 2013. Carboplatin/5-fluorouracil as an alternative to cisplatin/5-fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. *Asian Pacific Journal of Cancer Prevention*, 14(2), pp.1121-1126.
- Lantika, Y., Rusli, R. dan Ayu, W., 2017. Kajian pola pengobatan penderita kanker serviks pada pasien rawat inap di instalasi RSUD Abdul Wahab Sjahranie periode 2014-2015. *Jurnal Sains dan Kesehatan*, 1(8), pp.448-455.
- Lee, B., 2023. Cervical Cancer: Pharmacologic Management. *Cancer Therapy Advisor*, 9.

- Marchetti, C., De Felice, F., Di Pinto, A., D'Oria, O., Aleksa, N., Musella, A., Palaia, I., Muzii, L., Tombolini, V. dan Panici, P.B., 2018. Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. *Critical reviews in oncology/hematology*, 125, pp.30-34.
- Minion, L.E. and Tewari, K.S., 2017. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. *Expert review of anticancer therapy*, 17(3), pp.191-198.
- National Cancer Institute, 2024. Cervical Cancer Treatment. Available at: <https://www.cancer.gov/types/cervical> (Accessed: 15 October 2024).
- Negarandeh, R., Salehifar, E., Saghafi, F., Jalali, H., Janbabaei, G., Abdhaghghi, M.J. and Nosrati, A., 2020. Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. *BMC cancer*, 20(1), p.560.
- Oun, R., Moussa, Y.E. and Wheate, N.J., 2018. The side effects of platinum-based chemotherapy drugs: a review for chemists. *Dalton transactions*, 47(19), pp.6645-6653.
- Pervaiz, S., Homsy, S., Narula, N., Ngu, S. and Elsayegh, D., 2020. Bevacizumab-induced pneumonitis in a patient with metastatic colon cancer: a case report. *Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine*, 14, p.1179548420929285.

- Prabhu M, 2016. Eckert LO Development of World Health Organization (WHO) recommendations for appropriate clinical trial endpoints for next-generation Human Papillomavirus (HPV) vaccines. *Papillomavirus Res.*;2:185–9. doi: 10.1016/j.pvr.2016.10.002.
- Rania, J., Purba, A. and Avidar, A.R., 2024. Relationship between Comorbidity and Survival of Cervical Cancer: A Literature Review. *INTERNATIONAL JOURNAL*, 5(6).
- Romero-Masters, J.C., Lambert, P.F. dan Munger, K., 2022. Molecular mechanisms of MmuPV1 E6 and E7 and implications for human disease. *Viruses*, 14(10), p.2138.
- Salib, M.Y., Russell, J.H., Stewart, V.R., Sudderuddin, S.A., Barwick, T.D., Rockall, A.G. and Bharwani, N., 2020. 2018 FIGO staging classification for cervical cancer: added benefits of imaging. *Radiographics*, 40(6), pp.1807-1822.
- Sawa, A., Sato, R., Matsuo, T., Okazaki, M., Hashimoto, S., Iguchi-Manaka, A., Shimada, K., Mathis, B.J., Yamada, T., Machino, T. and Bando, H., 2025. Paclitaxel-induced peripheral neuropathy and quality of life: sub-analysis of the MICHEL study. *Anticancer Research*, 45(9), pp.3827-3833.
- Setiawati, S. and Hapsari, Y., 2023. Clinical Manifestations, Diagnosis, Management and Prevention of Cervical Cancer. *Jurnal Biologi Tropis*, 23(4), pp.382-390.
- Sugiyono, D., 2013. *Metode penelitian pendidikan pendekatan kuantitatif, kualitatif dan R&D*. Bandung: Alfabeta.

- Tao, W., Yang, J., Jiang, Y., Chen, W. and Wang, Y., 2020. Paclitaxel, carboplatin, and bevacizumab in advanced cervical cancer: a treatment response and safety analysis. *Dose-Response*, 18(3), p.1559325820941351.
- Tewari, K.S., Sill, M.W., Long III, H.J., Penson, R.T., Huang, H., Ramondetta, L.M., Landrum, L.M., Oaknin, A., Reid, T.J., Leitao, M.M. and Michael, H.E., 2014. Improved survival with bevacizumab in advanced cervical cancer. *New England Journal of Medicine*, 370(8), pp.734-743.
- Wang, X. and Cheng, Z., 2020. Cross-sectional studies: strengths, weaknesses, and recommendations. *Chest*, 158(1), pp.S65-S71.
- Wang X, Huang X, Zhang Y., 2018. Involvement of Human Papillomaviruses in Cervical Cancer. *Front Microbiol.* 9:2896.
- Wondm, S.A., Dagnew, S.B., Gubae, K., Tesfaye, T.C. and Tamene, F.B., 2024. Determinants of anemia among patients receiving cancer chemotherapy in Northwest Ethiopia. *Frontiers in Medicine*, 11, p.1415877.
- Wordeman, L. and Vicente, J.J., 2021. Microtubule targeting agents in disease: classic drugs, novel roles. *Cancers*, 13(22), p.5650.